8 results about "Dose-effect curve" patented technology

The invention discloses a method for detecting the biological activity of human immunoglobulin ADCP, which is characterized in that CHO-K1 / SPIKESARS2 is taken as a target cell, THP-1 cells (human leukemia monocytes which naturally express CD32a (Fc gamma RIIa) and CD64a (Fc gamma RIIa) and stably transfect NF-kB-Luc luciferase reporter genes) modified by genetic engineering are taken as effector cells, and a fluorescence reporter gene method is adopted for detection. Based on specific target cells and effector cells, the ADCP biological activity of two different human immune globulin preparations, namely intravenous injection human immune globulin and subcutaneous injection human immune globulin, can be accurately and reliably reflected by a drawn dose-effect curve through a detection system matched with specific human immune globulin solution concentration, and the method is simple and easy to implement. Cost is low, and practical application and popularization value is achieved.

The invention discloses a method for evaluating a hypothalamic-pituitary reproduction endocrine axis interference effect of a compound, and belongs to the technical field of chemical environmental health risk evaluation. A hypothalamic neuron cell line and a pituitary gonadotrophy cell line are selected as in-vitro evaluation models; the method comprises the following steps: obtaining an exposure concentration gradient of a compound influencing cell activity through cell culture and a cytotoxicity experiment, carrying out a cell exposure experiment on a hypothalamic neuron cell line and a pituitary gonadotrophy cell line at the exposure concentration gradient, and determining the expression quantity of a target gene in the cell after the exposure is finished, according to the exposure concentration gradient and the expression quantity of the target gene, obtaining a dose-effect curve of the compound interfering the expression of the target gene, and evaluating the interference effect of the compound on the hypothalamic-pituitary reproduction endocrine axis by using a toxicology priority index ToxPi, according to the method, high-throughput evaluation on the endocrine disruption effect of the hypothalamus-pituitary axis of the compound is realized.

The invention relates to the field of focused ultrasound, in particular to a parameter positioning method and kit for inhibiting PCOS concurrent epilepsy based on focused ultrasound. The method comprises the following steps: acquiring different power and duty ratio combinations corresponding to a plurality of preset gears; according to the prior experiment data and the biological thermal model, predicting safety intervals of stimulation duration under different gears, and setting a plurality of experiment parameter combinations of different preset doses according to the safety intervals; performing ultrasonic stimulation on the experimental model based on the experimental parameter combination to obtain a biological response result; based on a preset dose effect relationship, according to the biological response result, respectively fitting a dose effect curve under each gear; and determining an optimal dose range of each gear based on the dose effect curve, and performing feasibility evaluation on the optimal dose range to determine an optimal parameter combination of focused ultrasound. On the premise of simple experimental operation, short period and low cost, a relatively accurate and effective ultrasonic parameter range is efficiently determined, and support is provided for personalized medical treatment.

The embodiment of the invention provides a method and a device for predicting the bioequivalent concentration of an environmental endocrine disrupter. The method comprises the following steps: receiving living body exposure data when fish is exposed to environmental endocrine disrupters and in-vitro exposure data related to a toxic action pathway, which are sent by data acquisition equipment; wherein the living body exposure data comprises an external exposure concentration; inputting the external exposure concentration into a pre-constructed physiological toxicokinetic model to output the maximum steady-state plasma concentration; acquiring dose-effect curve data according to the in-vitro exposure data related to the toxic action pathway; acquiring in-vitro biological activity concentration from the dose-effect curve data; calculating a bioequivalent concentration according to the maximum steady-state plasma concentration and the in-vitro biological activity concentration; and sending the bio-equivalent concentration to a display terminal for display. According to the method, the bioequivalent concentration can be accurately predicted, so that the toxic effect of the target site concentration of the environmental endocrine disrupter on the fish is accurately evaluated.

This application relates to the field of focused ultrasound, and more particularly to a parameter localization method and kit for inhibiting PCOS-related epilepsy using focused ultrasound. The method includes: acquiring multiple preset power levels, each corresponding to different combinations of power and duty cycle; predicting the safe range of stimulation duration at different power levels based on prior experimental data and a biothermal model; setting several experimental parameter combinations with different preset doses based on the safe ranges; performing ultrasound stimulation on an experimental model based on the experimental parameter combinations and obtaining biological response results; fitting dose-response curves for each power level based on a preset dose-response relationship and the biological response results; determining the optimal dose range for each power level based on the dose-response curves, and evaluating the feasibility of the optimal dose range to determine the optimal parameter combination for focused ultrasound. This method efficiently determines a relatively accurate and effective range of ultrasound parameters while maintaining simple experimental operation, short cycle time, and low cost, providing support for personalized medicine.

The present invention belongs to the field of drug detection and specifically discloses a method for detecting the antibody-dependent cell-mediated cytotoxic biological activity of human immunoglobulin, comprising the following steps: 1) taking a target cell suspension and adding it to a well plate, then adding a series of concentrations of human immunoglobulin solutions for incubation, and finally adding an effector cell suspension for incubation; 2) taking the well plate incubated in step 1) to detect fluorescence, draw a dose-effect curve and calculate the half-maximal effective concentration; the target cells are CHO-K1 cells expressing the SARS-CoV-2 Spike protein, and the effector cells are Jurkat cells stably expressing CD16a on the cell membrane and stably transfected with the firefly luciferase gene driven by the NFAT response element. The detection method of the present invention can accurately and reliably detect the antibody-dependent cell-mediated cytotoxic biological activity of two different human immunoglobulin preparations, IVIG and SCIG.

The invention provides a drug random double-blind experiment system and method based on a virtual human body cluster, and is characterized in that a silicon-based subject cluster is used for replacing a traditional clinical test object, a virtual experiment normal form based on multi-scale physiological modeling and AI dynamic response is constructed, and a research and development process from drug discovery to clinical transformation is remodeled. According to the system core, a virtual subject generation module, a double-blind control module, a drug effect response prediction module and a verification interface form a closed loop. The method mainly comprises the steps of generating a virtual subject cluster, performing double-blind distribution of virtual drugs and placebo, running physiological simulation for 72 hours, performing AI analysis on a drug effect response matrix, performing statistics on significant differences after blind uncovering, and outputting a dose-effect curve.

The application discloses a method for evaluating the hypothalamus-pituitary reproductive endocrine axis interference effect of a compound, and belongs to the technical field of chemical environmental health risk evaluation. The hypothalamic neuron cell line and the pituitary gonadotropin cell line are selected as in-vitro evaluation models, the exposure concentration gradient of the compound affecting cell activity is obtained through cell culture and cytotoxicity experiment, the cell exposure experiment of the hypothalamic neuron cell line and the pituitary gonadotropin cell line is carried out at the exposure concentration gradient, the expression amount of a target gene in the cells is determined after the exposure is finished, the dose-effect curve of the compound interfering with the expression of the target gene is obtained according to the exposure concentration gradient and the expression amount of the target gene, and the interference effect of the compound on the hypothalamus-pituitary reproductive endocrine axis is evaluated by using a toxicology priority index ToxPi.